18 and older, any sex, with Opioid Use. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
MOUD Retention RatePrimary· Measured between participants' completion of baseline assessment and completion of the follow-up assessment (approximately 8-12 weeks following the intervention date).
Average number of days a participant missed an MOUD appointment between receiving the intervention and completing the follow-up assessment (approximately 8-12 weeks following the intervention date), averaged across all participants with available data.
Group
Value
95% CI
Peer-delivered Behavioral Activation
.42
± 2.86
Intervention Fidelity: Proportion of Intervention Components Delivered as IntendedPrimary· The number of days between starting the intervention and completing the intervention (approximately 8-10 weeks).
Defined as the proportion of all 24 intervention components in the total intervention that were delivered with fidelity by the interventionist (ranging from 0 to 1.0 with higher proportion reflecting more fidelity).
Group
Value
95% CI
Peer-delivered Behavioral Activation
.83
± .09
Intervention Acceptability: Percentage of Patients Enrolled Who Attend ≥75% SessionsSecondary· The number of days between starting the intervention and completing the intervention (approximately 8-10 weeks).
Defined as the percentage of participants who started the intervention who then finish the intervention (defined as completing 8 total sessions)
Group
Value
95% CI
Peer-delivered Behavioral Activation
62
Intervention Feasibility: Percentage of Patients Who Consents Who Started BASecondary· The number of days between starting providing consent and starting BA (approximately 1-5 weeks).
Defined as the percentage of participants who started BA sessions relative to those who enrolled in the program
Group
Value
95% CI
Peer-delivered Behavioral Activation
21
Sponsor's own description
This project aims to implement a peer-led intervention to support retention and adherence to medications for opioid use disorder among low-income adults in Detroit, as well as a training manual for peer recovery coaches serving similar populations. The approach will serve as a guide to coaches in providing positive reinforcement and helping those in treatment to schedule and engage in valued activities. Researchers will examine the effectiveness of the intervention, supervision and training models, and share results with policymakers and treatment programs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT06249386 — Adapting and Piloting Behavioral Activation for Veterans With Alcohol Use Disorder and Posttraumatic Stress Disorder
· NA
· completed
NCT03916276 — Living in Full Even With Pain Study
· NA
· completed
NCT03687762 — Back on Track to Healthy Living Study
· NA
· completed
NCT06170255 — Depression Treatment and Risk for Cardiovascular Disease
· Phase 1, PHASE2
· completed
NCT01299766 — Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
· Phase 3
· completed
Other recruiting trials for Opioid Use
Currently open trials in the same condition.
NCT07342504 — Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist
· NA
· recruiting
NCT07004686 — Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients
· NA
· recruiting
NCT06981195 — Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
· Phase 2
· recruiting
NCT06806163 — Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
· NA
· recruiting
NCT06909851 — Comparison of Pain Relief After Arthroscopic Knee Surgery: Adductor Canal Block and Genicular Nerve Block
· NA
· recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
· Phase 2
· not yet recruiting
NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries
· NA
· not yet recruiting
NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers
· NA
· recruiting
NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
Last refreshed: 14 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05098795.